signed an 8 year exclusivity agreement with Dacres, one of the north of England's largest independent estate agents, to deliver financial services to their extensive client base.
The AIM listed property franchise group has been diversifying into financial services, acquiring Brook Financial in 2017, and MAB Gloucester in 2018.
Belvoir said that the agreement with the 20 office estate agency network based in Yorkshire is expected to contribute to £100,000 in operating profit in the first year, and could grow from four advisers to ten in the next two years.
Dorian Gonsalves, CEO, commented; "Our diversification into financial services is proving to be a real win-win for the Group with growth arising from working with both our networks and independent agents."
He added: “We are really excited to be taking on the financial services for Dacres. Our financial services team based in Barnsley is well placed to support their network and is looking forward to working closely with their offices to build up the level of mortgage sales delivered to their clients."
Shares in Belvoir rose 2.97% to 121.5p during Thursday morning trading
Patrick McCutcheon, Residential MD of Dacres, commented; "Following a strategic review of our financial services offering undertaken in the spring of this year, we identified the financial services arm of Belvoir Group PLC as being a service provider with whom we would be very keen to work.”
He added: “We believe that their management share our values on customer service and growth, and can deliver what we require to satisfy our own internal needs as well as those of our valued customers. We are looking forward to engaging fully and working with the Belvoir Group team to drive our mortgage proposition to even greater heights."
Belvoir Group has 160 advisers operating across the North, the South West, the Midlands and Wales.
Belvoir’s financial services division has written 7,961 mortgages, contributing £1.9 million of gross profit to the Group's performance.
Follow News & Updates from Belvoir here:
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.
- i3 Energy’s CEO, Majid Shafiq and CFO, Graham Heath on the Gain Energy acquisition
7th Aug 2020Majid Shafiq, CEO of i3 Energy (AIM:I3E), and CFO, Graham Heath, discuss today’s follow-on deal to sell the Gain assets to Harvard Resources which will occur following the completion of the group’s previously announced C$80 million reverse takeover .
- i3 Energy FY19 Results and Proposed Placing to raise £30m
7th Aug 2020i3 Energy plc, an independent oil and gas company with assets and operations in the UK, Final Results for the year ended 31 December 2019 show significant operational progress for the pre-revenue company with net loss of £10.8m. To fund the Gain acquisition announced post period end in 2020, i3 is proposing to raise £30 million at a price of 5 pence per share, an 18% discount to the closing mid-price at which i3's shares suspended on 23 June 2020.
- OILEX Reaches Amicable Conclusion on the JPDA Proceedings
7th Aug 2020Oilex, the Operator of the PSC and on behalf of the JDPA joint venture, has reached amicable settlement with JPDA in East Timor with a settlement of US$0.8m payable in 2021 and 2022 financial years. The settlement amount is fully provided for in the FY19 accounts.
- Shield Therapeutics reports positive data from reanalysis study
7th Aug 2020Shield Therapeutics said a reanalysis of the AEGIS-H2H study for its iron deficiency lead product Feraccru®/Accrufer® has confirmed the product as a credible alternative to IV therapy for patients with iron deficiency anaemia.
